	Prospectos 1 477 1 6052,	
TEXTO 1 477 1 6051,	
	10 1 477 1 6045,	
RENOVACIÓN 1 477 1 6042,	
O 1 477 1 6039,	
PRIMERA 1 477 1 6037,	
FECHA 2 477 2 6034,6046,	
	 1 477 1 6032,	
COMERCIALIZACIÓN 1 477 1 6031,	
NÚMEROS 1 477 1 6027,	
­ 1 477 1 6024,	
(Navarra) 1 477 1 6023,	
31620-HUARTE-PAMPLONA 1 477 1 6022,	
Polígono 1 477 1 6020,	
Olaz-Chipi 1 477 1 6018,	
S 1 477 1 6016,	
COMERCIALIZACION 1 477 1 6013,	
AUTORIZACIÓN 3 477 3 6011,6029,6038,	
LA 5 477 5 6010,6036,6041,6044,6048,	
TITULAR 1 477 1 6008,	
normativas 1 477 1 6005,	
realizará 1 477 1 6000,	
contacto 1 477 1 5996,	
tamaños 1 477 1 5972,	
comercializados 1 477 1 5970,	
estén 1 477 1 5969,	
Puede 1 477 1 5966,	
56 2 477 2 5956,5964,	
Aluminio 2 477 2 5935,5937,	
acondicionan 1 477 1 5931,	
contenido 1 477 1 5925,	
requiere 1 477 1 5916,	
conservación 2 477 2 5914,5920,	
Precauciones 2 477 2 5911,5977,	
aplicable 1 477 1 5901,	
estearato 1 477 1 5894,	
crospovidona 1 477 1 5892,	
microcristalina 1 477 1 5888,	
Celulosa 1 477 1 5887,	
FARMACÉUTICOS 1 477 1 5881,	
" 1 477 1 5878,	
cabo 1 477 1 5873,	
llevados 1 477 1 5871,	
acuerdo 2 477 2 5867,6002,	
carcinogénica 1 477 1 5865,	
Carcinogénesis 1 477 1 5861,	
mamíferos 1 477 1 5860,	
bacteriana 1 477 1 5851,	
mutación 1 477 1 5850,	
amplia 1 477 1 5841,	
envase 2 477 2 5927,5974,	
mutagénica 1 477 1 5834,	
Mutagenicidad 1 477 1 5827,	
grado 1 477 1 5824,	
fetal 1 477 1 5816,	
desarrollo 1 477 1 5815,	
descendencia 1 477 1 5803,	
(9 1 477 1 5795,	
humanos) 2 477 2 5782,5801,	
(3 1 477 1 5776,	
alteraron 1 477 1 5769,	
menstruales 1 477 1 5764,	
ciclos 1 477 1 5763,	
apareamiento 1 477 1 5757,	
conducta 1 477 1 5755,	
modificó 1 477 1 5753,	
teratógeno 1 477 1 5748,	
presentado 2 477 2 5746,5832,	
ósea 1 477 1 5736,	
médula 1 477 1 5735,	
validez 1 477 1 5906,	
proliferación 1 477 1 5732,	
progenitoras 1 477 1 5727,	
células 1 477 1 5726,	
reciba 1 477 1 5708,	
hombre 1 477 1 5706,	
(la 1 477 1 5689,	
mg/kg/día 1 477 1 5682,	
ó 1 477 1 5680,	
Algunos 1 477 1 5675,	
citotoxicidad 1 477 1 5673,	
hallaron 1 477 1 5670,	
inespecífica 1 477 1 5658,	
circulantes 2 477 2 5652,5662,	
incluidas 1 477 1 5645,	
hematológicos 1 477 1 5644,	
especies 1 477 1 5637,	
hematológica 1 477 1 5633,	
glándula 1 477 1 5630,	
vagina 1 477 1 5626,	
serie 1 477 1 5842,	
epitelio 1 477 1 5623,	
morfológicos 1 477 1 5620,	
útero 1 477 1 5616,	
ovarios 1 477 1 5613,	
rata 3 477 3 5604,5665,5767,	
consonancia 1 477 1 5595,	
redujeron 1 477 1 5583,	
altas 1 477 1 5582,	
tolerancia 1 477 1 5574,	
desarrollaron 1 477 1 5573,	
hematológicas 1 477 1 5569,	
así 2 477 2 5566,5817,	
predominantes 1 477 1 5557,	
ratas 4 477 4 5552,5760,5806,5875,	
ratones 3 477 3 5545,5654,5877,	
semi-inconsciencia 1 477 1 5528,	
postración 1 477 1 5522,	
causaron 1 477 1 5518,	
orales 1 477 1 5512,	
monos 1 477 1 5509,	
anorexia 1 477 1 5506,	
miosis 1 477 1 5504,	
respiratorio 1 477 1 5503,	
consistieron 2 477 2 5494,5558,	
sufrir 1 477 1 5489,	
(ratas) 1 477 1 5476,	
175 1 477 1 5474,	
(ratones) 1 477 1 5472,	
mg/kg 6 477 6 5471,5475,5487,5517,5775,5794,	
mediana 1 477 1 5463,	
clónicas 1 477 1 5454,	
temblores 2 477 2 5452,5498,	
hipoactividad 1 477 1 5450,	
potentes 1 477 1 5449,	
característicos 1 477 1 5444,	
únicas) 1 477 1 5433,	
Toxicidad 4 477 4 5430,5529,5632,5737,	
ácida 1 477 1 5423,	
1-glucoproteína 1 477 1 5422,	
albúmina 1 477 1 5418,	
preferentemente 1 477 1 5415,	
une 1 477 1 5414,	
ng/ml 1 477 1 5410,	
93 1 477 1 5397,	
representa 1 477 1 5394,	
anemia 1 477 1 5687,	
plasmáticas 1 477 1 5393,	
magnesio 1 477 1 5896,	
proteínas 1 477 1 5392,	
poblaciones 1 477 1 5384,	
farmacocinéticos 1 477 1 5380,	
parámetros 4 477 4 5379,5585,5643,5785,	
encontraron 1 477 1 5375,	
chinos 1 477 1 5372,	
caucasianos 1 477 1 5369,	
pequeño 1 477 1 5352,	
impacto 1 477 1 5333,	
plasmático 1 477 1 5300,	
litros 1 477 1 5296,	
hombres) 1 477 1 5269,	
(mujeres 1 477 1 5267,	
l/hora 1 477 1 5257,	
h 1 477 1 5253,	
similar 1 477 1 5245,	
(39 1 477 1 5232,	
principalmente 1 477 1 5215,	
orina 1 477 1 5214,	
elimina 1 477 1 5211,	
57 1 477 1 5204,	
aproximadamente 4 477 4 5202,5395,5407,5469,	
masas 1 477 1 5198,	
balance 1 477 1 5196,	
Un 1 477 1 5193,	
(21 1 477 1 5186,	
(37 1 477 1 5175,	
hubo 1 477 1 5165,	
(aclaramiento 1 477 1 5154,	
deterioro 1 477 1 5152,	
(n=467) 1 477 1 5144,	
seguridad 2 477 2 5139,5429,	
(5-20 1 477 1 5133,	
l/hora) 3 477 3 5128,5192,5242,	
27 2 477 2 5126,5294,	
(18 3 477 3 5122,5240,5290,	
32 2 477 2 5114,5179,	
medida 1 477 1 5109,	
comparando 1 477 1 5092,	
diferenciado 1 477 1 5086,	
ancianos 2 477 2 5063,5308,	
variabilidad 2 477 2 5046,5357,	
litros/hora) 1 477 1 5044,	
reducido 2 477 2 5037,5287,	
horas) 5 477 5 5032,5116,5181,5234,5285,	
33 1 477 1 5030,	
prolongada 3 477 3 5025,5106,5271,	
semivida 5 477 5 5021,5102,5229,5276,5347,	
jóvenes 2 477 2 5016,5313,	
(65 1 477 1 5007,	
sexo 2 477 2 5000,5338,	
varió 1 477 1 4992,	
terminal 1 477 1 4983,	
vida 2 477 2 4981,5171,	
Después 1 477 1 4975,	
progenitor 1 477 1 4973,	
fármaco 1 477 1 4972,	
deriva 1 477 1 4970,	
farmacológica 2 477 2 4955,4968,	
2-hidroximetilo 1 477 1 4950,	
N-desmetilo 1 477 1 4948,	
metabolitos 2 477 2 4947,5219,	
síntesis 1 477 1 4944,	
citocromos 1 477 1 4937,	
hematoencefálica 1 477 1 4935,	
barrera 1 477 1 4934,	
traspasa 1 477 1 4932,	
10-N-glucurónido 1 477 1 4929,	
circulante 1 477 1 4926,	
conjugación 1 477 1 4920,	
hígado 1 477 1 4914,	
metaboliza 1 477 1 4911,	
intravenosa 1 477 1 4907,	
absoluta 1 477 1 4902,	
ingesta 1 477 1 4894,	
modifica 1 477 1 4891,	
Su 1 477 1 4887,	
alcanza 1 477 1 4878,	
plasmática 1 477 1 4875,	
oral; 1 477 1 4872,	
farmacocinéticas 1 477 1 4862,	
retraso 2 477 2 4851,5812,	
advirtieron 1 477 1 5721,	
sindrómico 1 477 1 4849,	
larga 1 477 1 4827,	
(litio 1 477 1 4819,	
estabilizadores 1 477 1 4816,	
3%; 1 477 1 4784,	
38 1 477 1 4783,	
30 3 477 3 4779,5283,5907,	
luego 1 477 1 4752,	
transitoria 1 477 1 5821,	
segundo 1 477 1 4723,	
frente 9 477 9 4701,5028,5040,5112,5124,5177,5188,5281,5292,	
ventaja 1 477 1 4698,	
principal 3 477 3 4683,4772,4924,	
superioridad 1 477 1 4675,	
aleatorizados 2 477 2 4666,4753,	
alcanzaron 2 477 2 4658,4740,	
maniaco 2 477 2 4656,4738,	
meses 5 477 5 4649,4731,4802,5540,5908,	
valproato) 2 477 2 4618,4821,	
Naturaleza 1 477 1 5923,	
(tratamiento 1 477 1 4612,	
25 1 477 1 5190,	
adición 1 477 1 4606,	
remisión 3 477 3 4572,4660,4742,	
predominante 1 477 1 4969,	
proporción 1 477 1 4568,	
términos 1 477 1 4565,	
resultados 2 477 2 4558,5095,	
maníacos 1 477 1 4537,	
reducir 1 477 1 4534,	
(-3 1 477 1 4518,	
atendiendo 1 477 1 4846,	
0) 1 477 1 4513,	
(-6 1 477 1 4512,	
001) 1 477 1 4507,	
dicha 1 477 1 4499,	
puntuación 1 477 1 4490,	
prospectivo 1 477 1 4485,	
secundario 1 477 1 4484,	
16 1 477 1 4480,	
valoración 3 477 3 4475,4685,4774,	
(puntuación 1 477 1 4466,	
depresivos 1 477 1 4464,	
grados 1 477 1 4461,	
determinado 1 477 1 4898,	
diferentes 2 477 2 4460,5361,	
481 1 477 1 4457,	
esquizoafectivo 1 477 1 4450,	
ciego 1 477 1 4445,	
comparativo 1 477 1 4443,	
comparador 1 477 1 4424,	
positivos 2 477 2 4404,4437,	
mejorías 1 477 1 4396,	
clozapina 1 477 1 4390,	
comparable 2 477 2 4383,5140,	
risperidona 1 477 1 4382,	
estriado 1 477 1 4370,	
reveló 1 477 1 4355,	
esquizofrénicos 2 477 2 4354,4432,	
SPECT 1 477 1 4351,	
Además 1 477 1 4345,	
HT2A 1 477 1 4335,	
ocupación 2 477 2 4330,4365,	
produjo 1 477 1 4328,	
sanos 5 477 5 4325,4991,5003,5163,5248,	
voluntarios 2 477 2 4324,4990,	
(10 1 477 1 4321,	
(TEP) 1 477 1 4317,	
positrones 1 477 1 4316,	
p 1 477 1 4785,	
emisión 1 477 1 4314,	
tomografía 1 477 1 4312,	
""ansiolítico"" 1 477 1 4307,	
contrario 1 477 1 4294,	
Al 1 477 1 4293,	
motoras 1 477 1 4292,	
catalepsia 1 477 1 4283,	
producen 1 477 1 4282,	
indicativo 2 477 2 4271,4288,	
test 2 477 2 4270,4306,	
condicionada 1 477 1 4268,	
evitación 1 477 1 4267,	
redujo 3 477 3 4263,5121,5237,	
motora 1 477 1 4260,	
(A9) 1 477 1 4255,	
estriadas 1 477 1 4254,	
vías 1 477 1 4253,	
escaso 1 477 1 4249,	
vez 1 477 1 4246,	
(A10) 1 477 1 4243,	
mesolímbicas 1 477 1 4242,	
dopaminérgicas 1 477 1 4241,	
neuronas 1 477 1 4240,	
selectiva 1 477 1 4235,	
demostraron 1 477 1 4228,	
Estudios 1 477 1 4226,	
modelos 1 477 1 4218,	
5HT2 2 477 2 4203,4220,	
demostró 5 477 5 4192,4501,4521,4556,4673,	
concordante 1 477 1 4182,	
5HT 1 477 1 4178,	
animales 3 477 3 4174,4965,5572,	
H1 1 477 1 4166,	
histamina 1 477 1 4165,	
adrenérgicos 1 477 1 4161,	
m1-m5; 1 477 1 4158,	
colinérgicos 1 477 1 4157,	
muscarínicos 1 477 1 4156,	
D5; 1 477 1 4154,	
D4 1 477 1 4152,	
D3 1 477 1 4151,	
D2 5 477 5 4150,4210,4225,4344,4368,	
5HT6; 1 477 1 4145,	
5HT3 1 477 1 4144,	
5HT2A/2C 1 477 1 4143,	
serotonina 2 477 2 4142,4202,	
nM) 1 477 1 4137,	
100 3 477 3 4136,5486,5516,	
(Ki; 1 477 1 4134,	
afinidades 1 477 1 4133,	
macho 1 477 1 5761,	
gama 1 477 1 4131,	
preclínicos 2 477 2 4126,5427,	
receptores 11 477 11 4123,4140,4146,4155,4159,4163,4200,4207,4333,4341,4367,	
sistemas 1 477 1 4122,	
número 1 477 1 4120,	
negativos 2 477 2 4407,4439,	
través 2 477 2 4117,4916,	
farmacológico 1 477 1 4115,	
perfil 4 477 4 4114,4185,5085,5137,	
afinidad 1 477 1 4194,	
amplio 1 477 1 4113,	
estabilizador 1 477 1 4106,	
antimaniaco 1 477 1 4104,	
agente 1 477 1 4102,	
H03 1 477 1 4097,	
N05A 1 477 1 4096,	
ATC 1 477 1 4095,	
código 1 477 1 4094,	
farmacoterapéutico 1 477 1 4092,	
Grupo 1 477 1 4091,	
farmacodinámicas 1 477 1 4090,	
ESTE 1 477 1 4085,	
DE 9 477 9 4084,6009,6012,6028,6030,6035,6040,6043,6047,	
FARMACOLÓGICAS 1 477 1 4083,	
PROPIEDADES 1 477 1 4082,	
supervisión 1 477 1 4074,	
estrecha 1 477 1 4073,	
continúe 1 477 1 4070,	
detectar 1 477 1 4062,	
estimulación 1 477 1 4049,	
puesto 1 477 1 4046,	
agonista 1 477 1 4044,	
simpaticomiméticos 1 477 1 4041,	
agentes 2 477 2 4040,4297,	
u 1 477 1 4038,	
dopamina 4 477 4 4037,4148,4209,4343,	
= 1 477 1 4786,	
adrenalina 1 477 1 4036,	
soporte 1 477 1 4027,	
circulatorio 1 477 1 4024,	
colapso 1 477 1 4023,	
vitales 1 477 1 4011,	
funciones 1 477 1 4010,	
sintomático 1 477 1 4006,	
instaurar 1 477 1 4003,	
activo) 1 477 1 3982,	
gástrico 1 477 1 3978,	
lavado 1 477 1 3977,	
estándar 1 477 1 3974,	
procedimientos 1 477 1 3973,	
encontraban 1 477 1 5606,	
emesis 1 477 1 3963,	
inducción 1 477 1 3960,	
antídoto 1 477 1 3952,	
supervivencia 1 477 1 3937,	
450 1 477 1 3928,	
bajas 1 477 1 3925,	
cantidades 1 477 1 3924,	
	6 1 477 1 5882,	
mortales 1 477 1 3919,	
cardiopulmonar 1 477 1 3914,	
parada 1 477 1 3913,	
Incompatibilidades 1 477 1 5899,	
2% 1 477 1 3906,	
(< 1 477 1 3904,	
arritmias 2 477 2 3902,4064,	
hipertensión 1 477 1 3899,	
locales 1 477 1 6006,	
ml/min) 1 477 1 5159,	
aspiración 1 477 1 3898,	
normalizadas 1 477 1 5845,	
respiratoria 2 477 2 3897,4031,	
delirium 1 477 1 3889,	
son 2 477 2 3888,5443,	
médicamente 1 477 1 3886,	
Otras 1 477 1 3881,	
diversos 1 477 1 3868,	
disartria 1 477 1 3865,	
agresividad 1 477 1 3864,	
agitación 1 477 1 3862,	
10%) 1 477 1 3858,	
> 1 477 1 3857,	
sobredosis 6 477 6 3853,3885,3921,3939,3948,3969,	
comunes 1 477 1 3850,	
Signos 1 477 1 3843,	
total 2 477 2 3839,5691,	
alcalina 1 477 1 3834,	
fosfatasa 1 477 1 3833,	
Aumento 1 477 1 3822,	
reproductor 1 477 1 3810,	
aparato 1 477 1 3809,	
Dificultad 1 477 1 3802,	
urinarios 1 477 1 3797,	
renales 1 477 1 3795,	
rash 1 477 1 3793,	
rabdomioólisis 1 477 1 3779,	
musculoesqueléticos 1 477 1 3770,	
colestático 1 477 1 3766,	
pancreatitis 1 477 1 3754,	
venosa 1 477 1 3746,	
trombosis 1 477 1 3745,	
pulmonar 1 477 1 3743,	
Tromboembolismo 1 477 1 3740,	
súbita 1 477 1 3722,	
ventricular/fibrilación 1 477 1 3719,	
Maligno 1 477 1 3664,	
utilizado 1 477 1 5986,	
Neuroléptico 1 477 1 3663,	
hipotermia 1 477 1 3610,	
hipercolesterolemia 1 477 1 3608,	
Hipertrigliceridemia 1 477 1 3607,	
14 1 477 1 5255,	
mencionada 1 477 1 3602,	
imagen 1 477 1 4349,	
espontáneamente 1 477 1 3579,	
urticaria 1 477 1 3559,	
prurito 1 477 1 3557,	
angioedema 1 477 1 3556,	
alérgica 1 477 1 3551,	
reacción 2 477 2 3550,3554,	
inmunológico 1 477 1 3545,	
trombocitopenia 2 477 2 3540,5685,	
leucopenia 1 477 1 3535,	
<1/1 4 477 4 3533,3618,3760,3791,	
(1/10 4 477 4 3531,3616,3758,3789,	
Raras 3 477 3 3530,3615,3788,	
comercialización 1 477 1 3521,	
tardíos 1 477 1 3502,	
extrapiramidales 2 477 2 3501,3867,	
síndromes 1 477 1 3500,	
y/u 1 477 1 3498,	
conclusión 1 477 1 3490,	
llegar 1 477 1 3487,	
actualidad 1 477 1 3483,	
tardías 1 477 1 3480,	
agudas 3 477 3 3478,3922,3940,	
extrapiramidal 1 477 1 3477,	
movimiento 1 477 1 3474,	
individuales 1 477 1 3470,	
detallada 1 477 1 3467,	
dispone 1 477 1 3464,	
haloperidol 3 477 3 3461,4517,4563,	
correspondientes 1 477 1 3459,	
presentaron 1 477 1 3446,	
numéricamente 1 477 1 3430,	
distonía 3 477 3 3423,3454,3681,	
01%) 1 477 1 3413,	
(<0 1 477 1 3412,	
escasas 1 477 1 3410,	
espontáneo 1 477 1 3407,	
comprendida 1 477 1 5056,	
observada 2 477 2 3397,5048,	
Sobredosis 1 477 1 3842,	
6% 1 477 1 3396,	
hiperglucemia) 1 477 1 3386,	
contribuyen 1 477 1 4941,	
9 4 477 4 3379,3841,5123,6033,	
0% 2 477 2 3360,3390,	
diabetes) 1 477 1 3356,	
mmol/l 4 477 4 3343,3353,3380,3383,	
ayunar 1 477 1 3332,	
creatinfosfoquinasa 1 477 1 3318,	
fuese 1 477 1 3305,	
normales 1 477 1 3302,	
mamas) 1 477 1 3289,	
Datos 1 477 1 5426,	
tamaño 1 477 1 3286,	
galactorrea 1 477 1 3282,	
ginecomastia 1 477 1 3281,	
(por 2 477 2 3279,3975,	
prolactina 2 477 2 3272,5601,	
Pruebas 2 477 2 3261,3820,	
edema 1 477 1 3260,	
generales 1 477 1 3249,	
fotosensibilidad 1 477 1 3247,	
subcutáneo 2 477 2 3239,3787,	
tejido 3 477 3 3238,3773,3786,	
piel 2 477 2 3236,3783,	
) 2 477 2 3232,3560,	
AST) 1 477 1 3220,	
(ALT 1 477 1 3219,	
oxidación 1 477 1 4922,	
asintomáticos 1 477 1 3212,	
hepatobiliares 2 477 2 3208,3756,	
doble 1 477 1 4444,	
incluyendo 1 477 1 3201,	
leves 1 477 1 3200,	
gastrointestinales 2 477 2 3194,3749,	
MINISTERIO 1 477 1 3192,	
ortostática 1 477 1 3191,	
vasculares 2 477 2 3187,3735,	
empleo) 2 477 2 3185,3733,	
prolongación 2 477 2 3171,3714,	
síncope 1 477 1 3170,	
(48 1 477 1 5251,	
bradicardia 1 477 1 3164,	
cardiacos 1 477 1 3158,	
continuación) 1 477 1 3156,	
parkinsonismo 4 477 4 3149,3421,3451,3680,	
acatisia 2 477 2 3148,3452,	
nota 3 477 3 3131,3153,3599,	
eosinofilia 1 477 1 3107,	
Frecuentes(1/100 7 477 7 3105,3121,3145,3188,3195,3209,3257,	
linfático 2 477 2 3104,3529,	
sangre 5 477 5 3100,3340,3351,3377,3525,	
Trastornos 21 477 21 3097,3108,3137,3157,3186,3193,3207,3233,3248,3522,3542,3561,3611,3708,3734,3748,3755,3769,3780,3794,3807,	
REVISIÓN 1 477 1 6049,	
complementarias 3 477 3 3092,3262,3821,	
tabla 2 477 2 3074,3505,	
siguiente 2 477 2 3073,3504,	
9% 2 477 2 3068,3366,	
39 1 477 1 3067,	
meses) 1 477 1 3040,	
(más 1 477 1 3037,	
semanas) 1 477 1 3026,	
(hasta 1 477 1 3024,	
fase 1 477 1 3020,	
4% 1 477 1 3010,	
ocurrió 1 477 1 3000,	
notificados 2 477 2 2985,3087,	
lenguaje 1 477 1 2982,	
boca 2 477 2 2971,3206,	
sequedad 2 477 2 2969,3204,	
(>10%) 1 477 1 2966,	
aumentados 1 477 1 2965,	
podrían 1 477 1 2947,	
elevados 4 477 4 2944,3129,3136,3316,	
1%; 1 477 1 2940,	
lugar 4 477 4 2932,2961,3254,4620,	
dio 3 477 3 2931,2960,4619,	
manía 3 477 3 2922,4577,4633,	
ensayo 1 477 1 2916,	
recuperación 1 477 1 4080,	
dopaminérgicos) 1 477 1 2887,	
(agonistas 1 477 1 2886,	
fármacos 1 477 1 2885,	
urinaria 1 477 1 2873,	
incontinencia 1 477 1 2872,	
visuales 1 477 1 2870,	
japoneses 1 477 1 5370,	
eritema 1 477 1 2868,	
anafilactoide 1 477 1 3555,	
temperatura 1 477 1 2865,	
<1/10) 9 477 9 2860,2988,3106,3122,3146,3189,3196,3210,3258,	
(1/100 2 477 2 2859,2987,	
observaron 2 477 2 2857,5639,	
caídas 1 477 1 2855,	
marcha 1 477 1 2853,	
asociado 2 477 2 2812,2952,	
realizados 3 477 3 2799,2878,5543,	
(1/10) 5 477 5 2781,2837,3117,3143,3265,	
adversas 8 477 8 2775,2778,2821,2834,3077,3508,4291,5089,	
motorizados 1 477 1 2771,	
vehículos 1 477 1 2770,	
maquinaria 1 477 1 2768,	
prevenidos 1 477 1 2763,	
mareos 1 477 1 2758,	
Puesto 1 477 1 2751,	
máquinas 2 477 2 2737,2750,	
utilizar 4 477 4 2736,2749,3972,4035,	
conducir 2 477 2 2734,2747,	
capacidad 2 477 2 2732,2745,	
Efectos 1 477 1 2729,	
tratadas 2 477 2 2724,5807,	
desaconsejar 1 477 1 2717,	
8% 1 477 1 2707,	
Cinfa 1 477 1 6015,	
estimó 1 477 1 2703,	
lactante 1 477 1 2701,	
compuestos 1 477 1 5447,	
(mg/kg) 2 477 2 2699,2714,	
sobredosis) 1 477 1 3911,	
materna 3 477 3 2692,2711,2720,	
leche 1 477 1 2691,	
excretó 1 477 1 2688,	
sanas 1 477 1 2682,	
Lactancia 1 477 1 2676,	
trimestre 1 477 1 2675,	
tercer 1 477 1 2674,	
usado 1 477 1 2670,	
madres 2 477 2 2668,2723,	
causar 1 477 1 2755,	
cuyas 1 477 1 2667,	
lactantes 1 477 1 2666,	
somnolencia 4 477 4 2664,2756,2791,3144,	
letargo 2 477 2 2662,2867,	
espontáneas 2 477 2 2658,3517,	
comunicaciones 2 477 2 2657,3516,	
recibido 1 477 1 2656,	
feto 1 477 1 2651,	
corporal 2 477 2 2866,3006,	
justifican 1 477 1 2645,	
beneficios 1 477 1 2643,	
sólo 1 477 1 2640,	
Montgomery-Asberg 1 477 1 4473,	
embarazo 1 477 1 2639,	
humana 1 477 1 2629,	
manera 2 477 2 2625,5244,	
quedarse 1 477 1 2616,	
piensan 1 477 1 2615,	
encuentran 2 477 2 2612,3860,	
médico 1 477 1 2609,	
notifiquen 1 477 1 2606,	
recomendar 1 477 1 2601,	
bilirrubina 1 477 1 3838,	
embarazadas 3 477 3 2598,2613,2617,	
adecuado 1 477 1 2592,	
ningún 2 477 2 2590,5084,	
lactancia 3 477 3 2586,2685,2719,	
embolismo 1 477 1 3742,	
Embarazo 2 477 2 2584,2587,	
introducción 1 477 1 2576,	
ajuste 1 477 1 2568,	
necesidad 1 477 1 2565,	
plasmáticos 3 477 3 2559,2943,3270,	
niveles 11 477 11 2558,2942,2964,3126,3133,3269,3297,3315,3335,3347,3373,	
biperideno 1 477 1 2552,	
administró 1 477 1 2547,	
reducía 1 477 1 4232,	
mostró 5 477 5 2543,4129,4248,4696,5810,	
2C19) 1 477 1 2539,	
diazepam 1 477 1 2536,	
(CYP1A2) 1 477 1 2534,	
(CYP2C9) 1 477 1 2532,	
ataxia 1 477 1 5497,	
warfarina 1 477 1 2531,	
mayoritariamente 1 477 1 2527,	
(metabolizados 1 477 1 2526,	
tricíclicos 1 477 1 2525,	
antidepresivos 1 477 1 2524,	
activos 1 477 1 2523,	
principios 1 477 1 2522,	
posible 1 477 1 3892,	
inhibición 1 477 1 2516,	
encontró 1 477 1 2514,	
vivo 4 477 4 2510,4215,4957,5858,	
comprobado 1 477 1 2506,	
especial 1 477 1 2500,	
espera 1 477 1 2497,	
De 2 477 2 2492,2623,	
potencial 1 477 1 2648,	
3A4) 1 477 1 2491,	
2C9 1 477 1 2489,	
2D6 1 477 1 2488,	
1A2 1 477 1 2487,	
j 2 477 2 2486,3553,	
Propiedades 2 477 2 4089,4861,	
(e 2 477 2 2485,3552,	
CYP450 1 477 1 2482,	
isoenzimas 1 477 1 2480,	
210 1 477 1 5470,	
principales 1 477 1 2479,	
cardíacas 1 477 1 3903,	
inhibe 1 477 1 2477,	
afecte 1 477 1 2456,	
cimetidina 1 477 1 2450,	
magnesio) 1 477 1 2448,	
(aluminio 1 477 1 2447,	
antiácidos 1 477 1 2446,	
únicas 2 477 2 2444,5513,	
CYP2D6) 2 477 2 2442,2530,	
(un 1 477 1 2439,	
(51 1 477 1 5026,	
fluoxetina 1 477 1 2438,	
iniciar 1 477 1 3804,	
significativo 1 477 1 2430,	
hallado 1 477 1 2427,	
60 2 477 2 2408,3999,	
50 2 477 2 2405,3997,	
activo 3 477 3 2395,3988,4425,	
carbón 3 477 3 2394,3981,3987,	
siguientes 1 477 1 2521,	
inicia 1 477 1 2381,	
ciprofloxacino 1 477 1 2368,	
colinérgico 1 477 1 4179,	
respectivamente 1 477 1 2344,	
108% 1 477 1 2343,	
52% 1 477 1 2341,	
curva 1 477 1 2336,	
área 1 477 1 2333,	
varones 2 477 2 2327,5320,	
77% 1 477 1 2325,	
fumadoras 1 477 1 2322,	
54% 1 477 1 2318,	
favorecía 1 477 1 4509,	
fluvoxamina 2 477 2 2315,2359,	
concentración 3 477 3 2306,4874,5403,	
medio 2 477 2 2303,2331,	
significativamente 3 477 3 2295,4837,4958,	
específico 2 477 2 2289,3953,	
inhibidor 4 477 4 2288,2363,2386,2440,	
2C19 1 477 1 2490,	
Fluvoxamina 1 477 1 2286,	
máxima 4 477 4 2307,4876,5780,5799,	
fuera 1 477 1 2270,	
monitorización 4 477 4 2266,2554,4059,4076,	
basales 1 477 1 3336,	
limitadas 1 477 1 2261,	
parecen 1 477 1 2259,	
consecuencias 2 477 2 2257,3882,	
diferencia 2 477 2 3434,5166,	
aclaramiento 8 477 8 2253,5035,5119,5185,5239,5289,5299,5344,	
reacciones 9 477 9 2777,2820,2833,3076,3245,3507,4290,4918,5088,	
leve 1 477 1 2248,	
Tan 1 477 1 2240,	
perros 4 477 4 5478,5554,5676,5716,	
concentraciones 1 477 1 2237,	
además 1 477 1 4025,	
carbamacepina 1 477 1 2221,	
tabaco 2 477 2 2218,5341,	
Inducción 1 477 1 2214,	
farmacocinética 3 477 3 2210,2433,5047,	
afectar 1 477 1 2208,	
inhibir 2 477 2 2204,2294,	
inducir 2 477 2 2202,2223,	
específicamente 1 477 1 2200,	
sustancias 1 477 1 2198,	
radiactiva 1 477 1 5209,	
CYP1A2 6 477 6 2196,2216,2285,2291,2365,2388,	
(38 1 477 1 5279,	
potenciales 2 477 2 2183,2644,	
Interacciones 1 477 1 2182,	
interacción 3 477 3 2163,2499,2544,	
(p=0 1 477 1 4506,	
formas 1 477 1 2161,	
Interacción 1 477 1 2154,	
glucosa 5 477 5 2144,3128,3338,3349,3375,	
problemas 1 477 1 2140,	
Lapp 1 477 1 2138,	
lactasa 1 477 1 2136,	
galactosa 2 477 2 2133,2146,	
intolerancia 1 477 1 2130,	
Tratamiento 1 477 1 3945,	
Este 1 477 1 2123,	
preventivas 1 477 1 2119,	
medidas 1 477 1 2118,	
hipertonía 1 477 1 2661,	
inmovilización 1 477 1 2113,	
ejemplo 4 477 4 2111,3280,3927,3976,	
identificar 1 477 1 2102,	
adquiridos 1 477 1 2096,	
menudo 1 477 1 2092,	
presentan 1 477 1 2090,	
causal 1 477 1 2070,	
nutrición 2 477 2 3114,3567,	
relación 1 477 1 2069,	
venoso 3 477 3 2063,2081,2099,	
tromboembolismo 3 477 3 2062,2080,2098,	
periféricas 1 477 1 5570,	
temporal 1 477 1 2056,	
raramente 2 477 2 2048,3274,	
Muy 16 477 16 2047,2652,3115,3141,3263,3536,3546,3568,3652,3710,3736,3750,3775,3798,3815,3826,	
hipomagnesemia 1 477 1 2046,	
congestiva 1 477 1 2041,	
cardiaca 2 477 2 2040,2043,	
prolongado 1 477 1 2038,	
congénito 1 477 1 2037,	
síndrome 2 477 2 2035,3893,	
aumentan 1 477 1 2022,	
cardíacos 2 477 2 2000,3709,	
eventos 1 477 1 1999,	
referente 2 477 2 1997,4706,	
diferencias 2 477 2 1989,5376,	
existiendo 1 477 1 1988,	
<1/100) 4 477 4 1981,3163,3244,3314,	
000 10 477 10 1980,3162,3243,3313,3329,3532,3617,3759,3790,5409,	
(1/1 4 477 4 1979,3161,3242,3312,	
frecuentes 9 477 9 1978,2780,2836,3116,3142,3160,3241,3264,3311,	
isoenzima 1 477 1 2206,	
msec) 1 477 1 1975,	
QTcF<500 1 477 1 1974,	
reproductora 2 477 2 5741,5789,	
basal 5 477 5 1972,3017,3064,4468,4493,	
situación 2 477 2 1971,4014,	
base 3 477 3 1966,3082,3513,	
línea 1 477 1 1964,	
posterior 1 477 1 1961,	
momento 2 477 2 1960,3016,	
mama 1 477 1 3814,	
[msec] 1 477 1 1957,	
milisegundos 1 477 1 1956,	
500 2 477 2 1955,3943,	
[QTcF] 1 477 1 1954,	
QT 3 477 3 1953,2036,3174,	
disquinesia 1 477 1 3150,	
Fridericia 1 477 1 1950,	
(corrección 1 477 1 1948,	
QTc 3 477 3 1947,2025,3717,	
intervalo 6 477 6 1946,1952,2024,3173,3716,5401,	
significativas 3 477 3 1944,1990,3887,	
ligera 1 477 1 5223,	
clínicamente 1 477 1 1943,	
mayores 4 477 4 1934,4395,5069,5526,	
periódicamente 1 477 1 1931,	
medir 1 477 1 1927,	
(AUC) 1 477 1 5694,	
infrecuente 1 477 1 1920,	
postural 1 477 1 1917,	
observó 1 477 1 1915,	
indirectos 2 477 2 1902,2473,	
directos 2 477 2 1900,2471,	
antagonizar 2 477 2 1893,2464,	
dopaminérgico 2 477 2 1887,4181,	
antagonismo 2 477 2 1886,4177,	
6) 1 477 1 4481,	
muestra 1 477 1 1885,	
Debido 1 477 1 1882,	
alcohol 1 477 1 1881,	
central 2 477 2 1878,2181,	
acción 1 477 1 1877,	
combine 1 477 1 1871,	
primarios 1 477 1 1859,	
cuenta 1 477 1 1856,	
Teniendo 1 477 1 1854,	
terminación 1 477 1 1851,	
después 7 477 7 1848,2310,2420,3518,4621,4664,4868,	
aparecer 1 477 1 1847,	
temporalmente 1 477 1 1844,	
empeorarse 1 477 1 1843,	
Estos 1 477 1 1840,	
suspensión 1 477 1 1836,	
tratado 1 477 1 1823,	
enfermo 1 477 1 1822,	
reversibles 2 477 2 5591,5688,	
apareciesen 1 477 1 1813,	
plazo 2 477 2 1808,4881,	
global 1 477 1 5358,	
exposición 3 477 3 1805,2696,5690,	
aumenta 2 477 2 1802,4301,	
relacionada 2 477 2 1791,4903,	
discinesia 6 477 6 1790,1800,1818,3147,3496,3683,	
significativa 7 477 7 1784,3436,4400,4505,4677,4700,5167,	
estadísticamente 8 477 8 1783,3435,4399,4504,4676,4699,4765,4839,	
comparables 1 477 1 4561,	
año 2 477 2 1772,5550,	
establecido 1 477 1 2067,	
comparativos 1 477 1 1769,	
estudios 8 477 8 1768,2508,2742,4125,4168,4963,5536,5870,	
tardía 5 477 5 1766,1801,1819,3497,3684,	
Discinesia 1 477 1 1765,	
existían 2 477 2 1755,3642,	
mayoría 3 477 3 1751,3292,3638,	
trata 1 477 1 1746,	
les 1 477 1 1745,	
aparecen 1 477 1 1736,	
descrito 1 477 1 1731,	
convulsivo 1 477 1 1728,	
bajar 1 477 1 1725,	
convulsiones 9 477 9 1716,1737,1758,1764,3627,3645,3651,3890,5453,	
antecedentes 4 477 4 1714,1756,3469,3643,	
enfermos 1 477 1 1712,	
antipsicóticos 5 477 5 1699,1924,2007,4298,4379,	
suspender 2 477 2 1695,3307,	
superior 3 477 3 4524,4838,5701,	
inexplicable 1 477 1 1686,	
alta 1 477 1 1685,	
fiebre 1 477 1 1684,	
desarrolla 1 477 1 1675,	
aguda 3 477 3 1671,3021,5431,	
e 6 477 6 1668,1901,2472,2871,3609,5856,	
(rabdomiólisis) 1 477 1 1667,	
mioglobinuria 1 477 1 1666,	
creatin- 1 477 1 1664,	
observa 1 477 1 1659,	
adicionales 2 477 2 1657,1690,	
Entre 3 477 3 1654,3846,5588,	
ritmo 1 477 1 1652,	
diaforesis 1 477 1 1648,	
efectos 8 477 8 1858,1895,2466,3197,5556,5564,5590,5722,	
taquicardia 4 477 4 1647,3718,3861,5499,	
hipotensión 6 477 6 1916,3168,3190,3901,4020,4054,	
irregulares 1 477 1 1646,	
hereditaria 1 477 1 2131,	
arterial 2 477 2 1645,1930,	
presión 2 477 2 1644,1929,	
profunda) 1 477 1 3747,	
(pulso 1 477 1 1642,	
autónomo 1 477 1 1641,	
nervioso 4 477 4 1640,2180,3140,3614,	
sistema 7 477 7 1639,2179,3103,3139,3528,3544,3613,	
inestabilidad 1 477 1 1637,	
mamaria 1 477 1 5631,	
conciencia 2 477 2 1633,3874,	
muscular 1 477 1 1630,	
rigidez 1 477 1 1629,	
hipertermia 1 477 1 1628,	
comprenden 1 477 1 1627,	
clínicas 4 477 4 1624,1689,2258,3278,	
puedan 2 477 2 1724,2201,	
manifestaciones 3 477 3 1623,1688,3277,	
presentaban 3 477 3 3334,4363,4434,	
Las 5 477 5 1622,2256,2776,2832,5580,	
pruebas 2 477 2 3091,5844,	
identificados 2 477 2 1615,3660,	
toleraron 1 477 1 5479,	
recogido 2 477 2 1613,3658,	
antipsicótica 2 477 2 1607,4275,	
apetito 2 477 2 2974,3125,	
medicación 2 477 2 1606,1839,	
asocia 1 477 1 1603,	
vital 1 477 1 1600,	
suponer 1 477 1 1598,	
roedores 1 477 1 5442,	
(SNM) 2 477 2 1590,3665,	
maligno 2 477 2 1589,3895,	
neuroléptico 2 477 2 1588,3894,	
Síndrome 2 477 2 1587,3662,	
5) 1 477 1 1586,	
farmacocinético 1 477 1 1582,	
realizado 6 477 6 1579,2741,2918,3080,3511,5366,	
conjunta 1 477 1 1574,	
reduce 2 477 2 2396,3989,	
SNM 5 477 5 1592,1617,1626,1681,1692,	
carbamazepina 1 477 1 1571,	
referentes 2 477 2 1549,1565,	
datos 2 477 2 1548,1563,	
triglicéridos 1 477 1 3135,	
8) 1 477 1 1545,	
valproato 13 477 13 1541,1556,2561,2573,2928,2946,2959,2999,4528,4599,4637,4834,4843,	
neutropenia 4 477 4 1533,2937,3541,5684,	
mieloproliferativa 1 477 1 1526,	
hipereosinofília 1 477 1 1522,	
radioterapia 1 477 1 1512,	
causadas 1 477 1 1508,	
fármacos; 1 477 1 1502,	
medular 3 477 3 1499,1507,5674,	
toxicidad 2 477 2 1498,5438,	
neutropenia; 1 477 1 1489,	
provocan 1 477 1 1488,	
conoce 1 477 1 1486,	
neutrófilos 1 477 1 1472,	
Areta 1 477 1 6021,	
leucocitos 3 477 3 1470,5651,5661,	
disponibles 1 477 1 1564,	
bajos 1 477 1 1468,	
recuentos 1 477 1 1467,	
clastogénica 1 477 1 5838,	
neurolépticos 2 477 2 1459,5448,	
Como 2 477 2 1456,1921,	
electrofisiológicos 1 477 1 4227,	
mixto) 2 477 2 1448,3768,	
colestásico 1 477 1 1446,	
daño 2 477 2 1444,3764,	
(incluyendo 3 477 3 1443,3741,3763,	
hepatitis 2 477 2 1442,3762,	
diagnostique 1 477 1 1441,	
priapismo 1 477 1 3819,	
produzca 2 477 2 1429,3494,	
hepatotóxicos 1 477 1 1414,	
potencialmente 2 477 2 1413,2951,	
medicamentos 8 477 8 1412,1481,1698,2018,2158,2173,2460,6054,	
están 3 477 3 1408,1719,5593,	
funcional 1 477 1 1401,	
reserva 1 477 1 1400,	
asociadas 3 477 3 1397,2782,2838,	
previas 1 477 1 1396,	
condiciones 2 477 2 1395,5917,	
/hora) 1 477 1 5297,	
historial 1 477 1 1494,	
hepática; 1 477 1 1391,	
disfunción 2 477 2 1390,5224,	
signos 8 477 8 1386,1635,1656,1676,1814,5435,5492,5671,	
elevada; 1 477 1 1382,	
tratamientos 1 477 1 1370,	
AST 3 477 3 1366,1381,1438,	
ALT 3 477 3 1365,1379,1436,	
hepáticas 2 477 2 1364,3218,	
blisters 1 477 1 5933,	
cardíaco) 1 477 1 1653,	
transaminasas 3 477 3 1363,3217,3825,	
transitorias 1 477 1 1360,	
(CYP3A4 1 477 1 2537,	
elevaciones 1 477 1 1357,	
observado 3 477 3 1356,2244,3367,	
Frecuentemente 1 477 1 1353,	
hipocalemia 1 477 1 2044,	
periodo 2 477 2 1352,3034,	
estrechamente 1 477 1 1346,	
controlado 1 477 1 2595,	
monitorizar 2 477 2 1345,4008,	
(olanzapina 1 477 1 4778,	
tardar 1 477 1 1340,	
aumentos 1 477 1 3211,	
hepatocelular 2 477 2 1445,3765,	
días 1 477 1 1338,	
producir 3 477 3 1334,2176,2232,	
antipsicótico 3 477 3 1326,4093,4103,	
Disminución 1 477 1 2389,	
establecida 1 477 1 1319,	
eficacia 3 477 3 1314,4523,4560,	
asociación 4 477 4 1307,1619,2055,3667,	
mixta 1 477 1 1294,	
salivación 1 477 1 5455,	
vascular 1 477 1 1292,	
75 1 477 1 1285,	
identificaron 1 477 1 1280,	
pre-existentes 1 477 1 1278,	
055) 1 477 1 4788,	
tenían 1 477 1 1274,	
adverso 1 477 1 1273,	
7% 2 477 2 3003,3058,	
acontecimiento 2 477 2 1272,3406,	
< 2 477 2 4135,5157,	
depresión 8 477 8 1496,1506,2177,3896,4478,4579,5560,5577,	
experimentaron 2 477 2 1267,5683,	
Todos 1 477 1 1258,	
0 6 477 6 1254,3365,4780,4787,5191,5241,	
posibles 2 477 2 2105,4063,	
(1 1 477 1 1250,	
comparado 1 477 1 1243,	
numero 1 477 1 1238,	
tres 4 477 4 1235,4419,4542,5383,	
transitoria) 1 477 1 1219,	
cerebral 1 477 1 1218,	
isquemia 1 477 1 1217,	
ictus 1 477 1 1216,	
demostrado 3 477 3 2293,4111,5200,	
cerebrovasculares 4 477 4 1213,1242,1305,2822,	
comunicaron 1 477 1 1210,	
(17 1 477 1 5038,	
independientemente 1 477 1 1198,	
benzodiacepinas 1 477 1 1176,	
concomitante 4 477 4 1174,1537,2581,3985,	
aspiración) 1 477 1 1171,	
teofilina 1 477 1 2533,	
neumonía 2 477 2 1167,2861,	
ej 2 477 2 1166,1215,	
(p 2 477 2 1165,1214,	
deshidratación 1 477 1 1162,	
malnutrición 1 477 1 1160,	
semisódico 1 477 1 4529,	
sedación 4 477 4 1159,3877,5496,5752,	
disfagia 1 477 1 1158,	
44 1 477 1 5065,	
>65 1 477 1 1156,	
incluyen 1 477 1 1154,	
población 1 477 1 1145,	
predisponer 1 477 1 1142,	
Los 12 477 12 1136,2127,2979,3441,4167,4936,5434,5477,5491,5571,5762,5928,	
duración 7 477 7 1133,1774,4651,4733,4804,4828,5542,	
(dosis 2 477 2 1123,5432,	
hayan 1 477 1 5993,	
estuvo 2 477 2 1116,2811,	
(E-460) 1 477 1 5889,	
respectivamente) 3 477 3 1109,1257,5258,	
vs 2 477 2 1105,1253,	
% 9 477 9 1104,1108,1252,1256,2409,4000,4781,5205,5398,	
( 1 477 1 1101,	
comparados 4 477 4 1094,2823,5160,5263,	
habían 1 477 1 2669,	
tratados 14 477 14 1091,1098,1188,1195,1229,1247,1261,1410,1984,3426,3443,3630,4595,5677,	
muerte 4 477 4 1087,1114,1182,3721,	
veces 5 477 5 1083,1236,5700,5777,5796,	
incrementó 2 477 2 1080,1233,	
78 1 477 1 1068,	
adversos 5 477 5 1212,1241,1304,3086,5723,	
media 10 477 10 1067,1124,2694,4467,4982,4986,5018,5099,5172,5273,	
(edad 1 477 1 1066,	
mortal 1 477 1 1225,	
duración) 1 477 1 1060,	
semanas 6 477 6 1058,1342,4543,4585,4604,4624,	
12 7 477 7 1057,3039,4584,4648,4730,5697,5712,	
(de 1 477 1 1054,	
controlados 3 477 3 1051,4412,4421,	
umbral 1 477 1 1727,	
cerebrovascular 2 477 2 1047,1270,	
(36 1 477 1 5110,	
P450-CYP1A2 1 477 1 4938,	
accidente 2 477 2 1046,1269,	
mortalidad 3 477 3 1041,1153,5490,	
empeorar 1 477 1 4052,	
incremento 9 477 9 1038,1150,1661,2246,2273,2302,2330,3002,3056,	
debido 1 477 1 1035,	
particular 1 477 1 1032,	
(indicadores 2 477 2 3354,3384,	
grupo 2 477 2 1031,2846,	
recomendándose 1 477 1 1026,	
demencia 4 477 4 1024,1078,1289,2806,	
asociados 7 477 7 1022,1076,1520,2001,2109,3275,4465,	
comportamiento 3 477 3 1021,1075,4170,	
trastornos 7 477 7 1019,1073,1519,1650,2850,2980,4452,	
juicio 1 477 1 1006,	
creatinina 1 477 1 5156,	
máximo 1 477 1 1001,	
valoró 1 477 1 996,	
comenzó 1 477 1 984,	
estudio 13 477 13 982,1581,2591,2679,4310,4347,4442,4588,4642,4724,4791,5194,5365,	
elevación 1 477 1 1434,	
asintomáticas 1 477 1 1358,	
dopaminérgico) 1 477 1 968,	
(agonista 1 477 1 967,	
antiparkinsoniano 2 477 2 966,977,	
menor 6 477 6 962,1787,3448,4371,4959,5305,	
estabilización 1 477 1 956,	
previa 1 477 1 955,	
requirió 1 477 1 953,	
psicóticos 1 477 1 947,	
adversas) 1 477 1 932,	
Reacciones 2 477 2 931,2774,	
placebo 18 477 18 925,940,1053,1100,1197,1249,1265,1994,2825,2913,3369,3399,3440,4414,4526,4670,4679,4703,	
frecuencia 2 477 2 922,2910,	
eliminación 8 477 8 4985,5023,5104,5174,5231,5278,5980,5982,	
frecuentemente 5 477 5 918,1530,2858,2906,2986,	
alucinaciones 3 477 3 916,2869,2904,	
parkinsoniana 2 477 2 914,2902,	
sintomatología 2 477 2 913,2901,	
empeoramiento 2 477 2 910,2898,	
Parkinson 2 477 2 901,2893,	
(n=869) 1 477 1 5148,	
enfermedad 3 477 3 899,1525,2891,	
usados 1 477 1 895,	
dopaminérgicos 3 477 3 894,1899,2470,	
agonistas 3 477 3 893,1898,2469,	
inducida 3 477 3 891,1500,2883,	
psicosis 4 477 4 890,1017,1071,2882,	
múltiples 1 477 1 5533,	
relacionadas 2 477 2 877,4256,	
paralítico 1 477 1 874,	
íleo 1 477 1 873,	
prostática 1 477 1 871,	
hipertrofia 2 477 2 870,2042,	
	"5 1 477 1 4087,	
prescriba 2 477 2 865,2014,	
limitada 3 477 3 859,1403,2631,	
letales 1 477 1 5467,	
enfermedades 4 477 4 856,876,1163,1510,	
embargo 9 477 9 845,1178,1576,1796,2003,2083,5130,5331,5667,	
Sin 8 477 8 844,1177,1795,2002,2082,5129,5330,5666,	
micción 1 477 1 3806,	
relacionados 2 477 2 843,4453,	
baja 1 477 1 839,	
ensayos 18 477 18 834,904,950,1049,1207,1322,1905,1939,2788,2797,2876,3095,3321,3416,4411,4420,5848,5853,	
vitro 5 477 5 829,1889,2484,4196,5855,	
in 8 477 8 828,1888,2483,2509,4195,4956,5854,5857,	
anticolinérgica 1 477 1 827,	
indicó 1 477 1 2563,	
actividad 10 477 10 826,4043,4213,4237,4274,4954,4967,5826,5833,5837,	
mostrado 2 477 2 824,837,	
concomitantes 3 477 3 819,857,1511,	
Enfermedades 1 477 1 818,	
retirar 1 477 1 813,	
reducción 10 477 10 807,1423,1830,2234,2373,3870,4628,5457,5647,5657,	
Debe 1 477 1 804,	
repentinamente 2 477 2 803,3707,	
interrumpir 3 477 3 798,1451,3702,	
vómitos 2 477 2 796,3700,	
nauseas 2 477 2 794,3698,	
ansiedad 2 477 2 793,3697,	
temblor 4 477 4 792,2660,2968,3696,	
insomnio 2 477 2 791,3695,	
sudoración 2 477 2 790,3694,	
agudos 2 477 2 787,3691,	
estreñimiento 1 477 1 3202,	
000) 17 477 17 785,2050,3534,3539,3549,3571,3619,3655,3713,3739,3753,3761,3778,3792,3801,3818,3829,	
(<1/10 13 477 13 784,2049,3538,3548,3570,3654,3712,3738,3752,3777,3800,3817,3828,	
escasamente 4 477 4 783,2653,3679,3689,	
mellitus 1 477 1 778,	
desarrollar 1 477 1 776,	
avanzada 6 477 6 1065,1913,2031,2804,5006,5054,	
diabéticos 1 477 1 768,	
especialmente 4 477 4 764,1367,2026,3221,	
apropiado 1 477 1 763,	
seguimiento 2 477 2 761,1419,	
Poco 3 477 3 3159,3240,3310,	
incidencia 12 477 12 840,1085,1112,1180,1788,2816,2935,3345,3371,3419,3449,3856,	
aconsejable 1 477 1 759,	
Es 3 477 3 758,4055,4065,	
años) 2 477 2 1069,5010,	
predisponente 1 477 1 757,	
peso 8 477 8 750,2795,2978,3005,3060,3120,5461,5610,	
previo 1 477 1 748,	
informado 2 477 2 744,3622,	
fatal 2 477 2 738,3596,	
desenlace 3 477 3 737,1224,3595,	
coma 5 477 5 734,3592,3880,3891,5451,	
indicativos 1 477 1 1679,	
cetoacidosis 2 477 2 732,3590,	
asociada 4 477 4 730,1117,2888,3588,	
ocasionalmente 2 477 2 729,3587,	
diabetes 3 477 3 728,777,3586,	
exacerbación 2 477 2 726,3584,	
aparición 5 477 5 724,1301,2078,3582,3625,	
anticolinérgicos 2 477 2 3198,5565,	
hiperglucemia 3 477 3 722,3403,3580,	
notificado 12 477 12 719,781,908,1529,2053,2896,3402,3578,3677,3687,3917,3934,	
raras 17 477 17 715,1609,1734,3537,3547,3569,3574,3634,3653,3711,3737,3751,3757,3776,3799,3816,3827,	
especiales 6 477 6 710,3183,3731,5912,5918,5978,	
precauciones 6 477 6 709,1375,1463,2011,3182,3730,	
Advertencias 4 477 4 707,2120,3180,3728,	
multinacional 1 477 1 4446,	
estrecho 1 477 1 704,	
ángulo 1 477 1 703,	
glaucoma 1 477 1 701,	
conocido 1 477 1 699,	
riesgo 14 477 14 698,774,1044,1139,1203,1277,1298,1599,1762,1798,2095,2108,2647,3649,	
Hipersensibilidad 1 477 1 686,	
Contraindicaciones 1 477 1 685,	
2) 2 477 2 682,2282,	
presentó 1 477 1 5135,	
combinada 1 477 1 2926,	
secciones 1 477 1 677,	
(Ver 2 477 2 674,3151,	
11 2 477 2 3352,3382,	
prudencia 2 477 2 670,1868,	
final 1 477 1 4497,	
hacerse 1 477 1 668,	
indicado 1 477 1 666,	
escalado 1 477 1 660,	
El 9 477 9 659,2217,2301,2329,2393,3027,4923,5298,5749,	
tabáquico) 1 477 1 648,	
materiales 1 477 1 5991,	
Inhibición 1 477 1 2283,	
hábito 1 477 1 647,	
ausencia 1 477 1 645,	
geriátrica 1 477 1 644,	
edad 11 477 11 643,1064,1155,1282,1912,2030,2803,4997,5005,5053,5336,	
femenino 1 477 1 642,	
(sexo 1 477 1 641,	
metabolismo 6 477 6 640,2225,2297,2518,3110,3563,	
enlentecimiento 1 477 1 638,	
resultar 1 477 1 636,	
pueda 1 477 1 635,	
factor 3 477 3 633,756,2950,	
presente 1 477 1 629,	
esté 1 477 1 628,	
Cuando 2 477 2 627,1439,	
fumadores 9 477 9 609,626,2328,5221,5250,5262,5266,5325,5329,	
hombres 3 477 3 603,5097,5147,	
absorbe 1 477 1 4866,	
comparación 9 477 9 600,623,1992,3362,3392,3456,4515,5012,5354,	
dosificación 2 477 2 598,621,	
volvieron 1 477 1 3298,	
nivel 3 477 3 596,619,3872,	
litio 13 477 13 1554,2550,2957,2997,4597,4616,4635,4749,4758,4768,4782,4832,4841,	
alterar 2 477 2 590,613,	
necesario 6 477 6 589,612,2271,3306,4056,4066,	
Fumadores 1 477 1 604,	
mujeres 8 477 8 586,2320,2597,2604,2681,5091,5143,5316,	
Generalmente 2 477 2 583,605,	
Sexo 1 477 1 582,	
precaución 4 477 4 581,862,1709,2167,	
D1 1 477 1 4149,	
deben 8 477 8 577,1373,1461,1694,2009,2101,2148,2761,	
incrementos 1 477 1 575,	
comienzo 2 477 2 568,3223,	
Child-Pugh) 1 477 1 564,	
	Laboratorios 1 477 1 6014,	
Lista 1 477 1 5884,	
escala 3 477 3 563,4471,4500,	
B 1 477 1 560,	
A 2 477 2 558,6017,	
clase 1 477 1 557,	
autorizada 1 477 1 1012,	
(cirrosis 1 477 1 556,	
insuficiencia 4 477 4 553,1669,2039,2134,	
casos 11 477 11 551,720,741,1531,1614,1754,3641,3659,3909,3918,3935,	
tipo 4 477 4 547,1291,1740,3476,	
estabilizados 1 477 1 4812,	
transitorios 2 477 2 3199,3214,	
mg) 5 477 5 544,1129,4322,5134,5713,	
inferiores 2 477 2 542,4278,	
iniciales 2 477 2 541,1371,	
utilización 1 477 1 538,	
considerarse 2 477 2 536,805,	
hepática 4 477 4 534,554,1402,5225,	
y/o 8 477 8 533,723,1018,1072,1380,1437,1471,3581,	
función 6 477 6 531,4030,4259,4994,5740,5788,	
alteraciones 5 477 5 528,1631,3251,3472,5568,	
Pacientes 2 477 2 526,696,	
4) 4 477 4 525,2831,3606,3674,	
requieran 1 477 1 520,	
clínicos 15 477 15 518,835,905,951,1050,1208,1906,1940,2789,2798,2877,3096,3322,3417,5493,	
Riesgo 1 477 1 2451,	
factores 11 477 11 517,772,1137,1201,1275,1296,1722,1760,2093,2106,3647,	
beta 2 477 2 4045,4050,	
astenia 1 477 1 3259,	
65 3 477 3 511,1936,5071,	
personas 1 477 1 509,	
considerada 1 477 1 507,	
rutina 1 477 1 503,	
mg/día) 1 477 1 498,	
incluía 1 477 1 4455,	
(5 2 477 2 497,543,	
inferior 3 477 3 496,2353,4766,	
Una 1 477 1 493,	
Ancianos 1 477 1 492,	
años 6 477 6 491,512,1157,1286,1937,5072,	
18 3 477 3 490,4801,5042,	
sujetos 10 477 10 487,1720,5002,5014,5051,5260,5265,5312,5362,5368,	
quimioterapia 1 477 1 1514,	
niños 1 477 1 485,	
experiencia 4 477 4 483,831,849,2628,	
hay 4 477 4 482,1562,2589,3950,	
No 13 477 13 481,878,1561,2064,2424,2738,3462,3949,3956,4032,4895,5900,5915,	
adolescentes 1 477 1 480,	
Niños 1 477 1 478,	
abandonar 1 477 1 473,	
900 1 477 1 4430,	
hora 2 477 2 471,4532,	
gradual 2 477 2 465,808,	
disminución 4 477 4 464,653,5608,5820,	
considerar 7 477 7 462,651,1421,1828,2268,2347,2371,	
Se 20 477 20 460,779,983,1279,1343,1372,1415,1527,1729,2164,2345,2369,2599,2715,2856,3400,3675,3685,3915,4001,	
absorción 3 477 3 459,2142,4888,	
afectan 2 477 2 457,2185,	
Período 1 477 1 5904,	
alimentos 1 477 1 455,	
receptor 1 477 1 4189,	
comidas 1 477 1 451,	
administrada 3 477 3 447,1707,2955,	
Olanzapina 6 477 6 444,1009,4391,4520,4554,5862,	
indicaron 1 477 1 4175,	
horas 3 477 3 443,2417,4886,	
24 1 477 1 442,	
menores 2 477 2 440,488,	
intervalos 2 477 2 438,3301,	
general 1 477 1 436,	
realizar 1 477 1 434,	
debería 2 477 2 433,461,	
vista 1 477 1 429,	
punto 2 477 2 427,4496,	
adecuadamente 1 477 1 422,	
España 1 477 1 6025,	
evaluar 1 477 1 421,	
mayor 12 477 12 413,921,1111,1184,1283,2815,2909,3431,4197,4212,4336,4627,	
aumento 16 477 16 409,747,998,2793,2862,2972,2976,3118,3123,3266,3284,3830,3835,5459,5500,5598,	
recomienda 7 477 7 407,861,880,1867,1926,2264,3958,	
Solo 1 477 1 405,	
20 2 477 2 401,5078,	
rango 2 477 2 397,5059,	
paciente 5 477 5 394,1331,1674,2115,4069,	
prolongó 1 477 1 5227,	
basándose 1 477 1 388,	
posteriormente 1 477 1 387,	
ajustarse 1 477 1 386,	
metabolizada 1 477 1 2193,	
podría 2 477 2 385,4051,	
Durante 5 477 5 367,1323,1903,2989,5534,	
clínico 5 477 5 366,392,430,762,2917,	
criterio 4 477 4 365,4682,4771,4848,	
ánimo 3 477 3 363,4108,4818,	
crecimiento 1 477 1 5587,	
acontecimientos 5 477 5 842,1211,1240,1303,3085,	
síntomas 17 477 17 359,786,946,1388,1678,1816,1841,3690,3845,3848,3866,4403,4436,4463,4536,4575,4631,	
análisis 1 477 1 4483,	
tratar 1 477 1 357,	
complementaria 1 477 1 355,	
necesario) 1 477 1 351,	
sea 1 477 1 350,	
prolongaciones 1 477 1 1942,	
según 3 477 3 349,364,4012,	
óptima 1 477 1 348,	
(con 2 477 2 345,3854,	
debe 20 477 20 338,505,535,569,650,667,1344,1416,1450,1705,1827,2165,2346,2370,2412,2600,2635,2716,4002,4034,	
moderada 1 477 1 555,	
depresivo 2 477 2 336,4720,	
mixto 3 477 3 334,4550,4811,	
nuevo 2 477 2 331,424,	
presenta 2 477 2 329,1683,	
Si 2 477 2 327,1672,	
continuar 3 477 3 314,339,970,	
conjuntamente 1 477 1 2548,	
tomando 1 477 1 306,	
han 13 477 13 304,718,780,1355,1528,1612,2655,2740,3657,3676,3686,3916,3933,	
En 36 477 36 300,550,713,739,902,948,1048,1204,1226,1608,1749,1938,2796,2874,2914,3290,3320,3415,3481,3636,4124,4308,4440,4586,4640,4721,4789,5001,5064,5090,5149,5220,5259,5363,5507,5714,	
mg/día 4 477 4 299,993,1004,5079,	
inicio 3 477 3 294,419,658,	
recaída 6 477 6 286,4688,4710,4717,4777,4854,	
Prevención 1 477 1 283,	
muertes 1 477 1 2818,	
combinación 7 477 7 278,2995,4592,4614,4745,4799,4825,	
monoterapia 4 477 4 267,4639,4760,4845,	
diaria 3 477 3 265,384,1125,	
única 3 477 3 264,4320,5483,	
15 3 477 3 260,1003,5699,	
día 3 477 3 252,273,404,	
recomendada 3 477 3 244,295,417,	
dosis 45 477 45 242,256,263,292,318,347,383,412,416,468,494,540,566,592,615,656,663,811,963,974,987,1120,1426,1833,2276,2349,2376,2443,2571,2710,3458,4277,4319,5074,5466,5481,5511,5525,5532,5581,5710,5771,5779,5791,5798,	
Esquizofrenia 1 477 1 240,	
conjuntivo 1 477 1 3774,	
oral 7 477 7 239,2402,3992,4901,4979,5439,5482,	
vía 1 477 1 238,	
metabolito 1 477 1 4925,	
Por 1 477 1 237,	
efecto 4 477 4 2429,4250,4287,5747,	
administración 8 477 8 236,2313,3256,3979,3984,4871,4906,4978,	
forma 6 477 6 234,1782,1919,4234,4398,5217,	
Posología 1 477 1 232,	
1) 5 477 5 229,282,1560,3132,4519,	
apartado 6 477 6 227,280,1543,1558,1584,2280,	
(ver 15 477 15 226,279,521,926,1542,1557,1583,2279,2826,3130,3175,3226,3597,3670,3723,	
P450-CYP2D6 1 477 1 4940,	
respondido 1 477 1 221,	
cuyo 1 477 1 217,	
SNC 3 477 3 1865,5562,5579,	
bipolar 7 477 7 216,290,2923,3051,4553,4692,4858,	
trastorno 8 477 8 215,289,1595,3050,4449,4552,4691,4857,	
citopenia 1 477 1 5718,	
recaídas 7 477 7 211,326,381,3046,4646,4728,4795,	
prevención 7 477 7 208,323,379,3043,4644,4726,4793,	
grave 1 477 1 201,	
equilibrio 1 477 1 2698,	
o 63 477 63 200,268,335,449,513,559,690,725,733,795,872,1130,1169,1172,1339,1447,1513,1523,1555,1643,1682,1717,1759,1775,1815,1834,1845,1879,2045,2139,2145,2203,2360,2419,2449,2535,2551,2614,2958,2998,3166,3169,3558,3583,3591,3646,3699,3767,3900,4549,4598,4617,4636,4669,4756,4810,4820,4833,4842,5008,5339,5686,5728,	
dosis-dependiente 1 477 1 5648,	
moderado 2 477 2 199,2250,	
maníaco 9 477 9 198,219,254,313,333,375,4548,4713,4809,	
unión 2 477 2 4187,5386,	
episodio 11 477 11 197,218,312,332,374,4547,4655,4712,4719,4737,4808,	
asoció 4 477 4 1780,3053,4393,5082,	
inicial 7 477 7 188,243,257,495,593,616,2350,	
cambios 2 477 2 5619,5640,	
terapéutica 2 477 2 187,2555,	
respuesta 6 477 6 186,4265,4303,4360,4376,4388,	
muestran 1 477 1 184,	
pacientes 71 477 71 182,213,302,549,673,767,770,854,868,897,959,1034,1062,1090,1097,1147,1187,1194,1228,1246,1260,1349,1377,1384,1393,1406,1465,1477,1491,1504,1517,1742,1910,1933,1968,1983,2028,2033,2087,2128,2169,2355,2760,2801,2848,2880,2920,3013,3048,3071,3295,3330,3425,3442,3629,4353,4358,4374,4386,4431,4458,4545,4570,4594,4653,4735,4806,5066,5150,5162,5247,	
continuación 1 477 1 179,	
biodisponibilidad 4 477 4 2392,2398,3991,4900,	
terapia 4 477 4 177,354,1573,2925,	
durante 10 477 10 175,832,1350,1430,2618,2672,2683,3018,3031,4600,	
clínica 5 477 5 174,850,1329,4015,4077,	
mejoría 3 477 3 173,1328,4503,	
mantenimiento 1 477 1 170,	
efectiva 3 477 3 167,938,964,	
esquizofrenia 5 477 5 163,372,2089,4448,5068,	
tratamiento 42 477 42 160,195,223,276,310,321,342,369,475,800,815,887,943,1015,1135,1310,1325,1432,1453,1479,1794,1853,2058,2073,2171,2357,2383,2580,2620,2808,2991,3023,3028,3225,3309,3704,3966,4005,4017,4590,4797,4823,	
indicada 4 477 4 157,192,205,501,	
está 7 477 7 156,191,204,500,665,1011,5055,	
La 34 477 34 154,164,189,202,241,255,291,1110,1313,1703,2474,2540,2553,2693,2953,3072,3370,3503,3983,4098,4190,4261,4693,4863,4908,4966,5045,5385,5411,5462,5742,5802,5828,5981,	
terapéuticas 1 477 1 153,	
Indicaciones 1 477 1 152,	
/ 4 477 4 1293,1497,3863,5936,	
	4 1 477 1 150,	
pulmonares 1 477 1 1164,	
CLÍNICOS 1 477 1 149,	
DATOS 2 477 2 148,5880,	
4 32 477 32 147,230,524,678,683,705,706,929,1127,1128,1255,1544,1585,2152,2281,2582,2727,2772,2830,2939,3178,3179,3230,3231,3605,3673,3726,3727,3840,5180,5284,5910,	
amarillo 1 477 1 146,	
color 1 477 1 145,	
biconvexos 1 477 1 142,	
cilíndricos 1 477 1 141,	
Comprimidos 1 477 1 140,	
	Comprimido 1 477 1 139,	
FARMACÉUTICA 1 477 1 138,	
FORMA 1 477 1 137,	
sección 9 477 9 133,523,928,2829,3177,3229,3604,3672,3725,	
mostraron 1 477 1 4952,	
ver 1 477 1 132,	
fosfoquinasa 1 477 1 1665,	
excipientes 4 477 4 131,695,2122,5886,	
completa 1 477 1 129,	
lista 1 477 1 128,	
Para 2 477 2 126,3964,	
8 11 477 11 121,930,2773,3342,3378,4885,5027,5031,5252,5679,6026,	
68 1 477 1 120,	
6 16 477 16 103,134,1055,2583,3025,4582,4623,5280,5291,5879,5897,5902,5909,5921,5975,5976,	
motivo; 1 477 1 1475,	
51 1 477 1 102,	
3 12 477 12 83,136,684,1102,1251,5115,5127,5233,5425,5539,5793,5903,	
34 1 477 1 82,	
conjunto 1 477 1 1552,	
contiene 4 477 4 76,95,114,2125,	
cambio 1 477 1 4487,	
Cada 3 477 3 70,88,108,	
monohidrato 5 477 5 69,87,107,125,5891,	
renal 3 477 3 532,1670,5153,	
lactosa 6 477 6 68,86,106,124,2126,5890,	
gr 4 477 4 66,84,104,122,	
17 2 477 2 64,3009,	
contiene2 1 477 1 58,	
comprimido 4 477 4 52,71,89,109,	
Episodio 1 477 1 253,	
	Cada 1 477 1 51,	
CUANTITATIVA 1 477 1 50,	
Y 1 477 1 49,	
CUALITATIVA 1 477 1 48,	
COMPOSICIÓN 1 477 1 47,	
10 11 477 11 42,112,115,249,270,298,4608,5158,5681,5960,6019,	
Existen 1 477 1 1546,	
7 11 477 11 35,92,96,2728,3341,5111,5176,5295,5405,5953,6007,	
olanzapina 134 477 134 27,33,40,53,62,72,80,90,100,110,118,155,165,190,203,225,246,307,344,477,689,802,817,822,852,866,884,934,989,1093,1122,1190,1231,1263,1312,1316,1455,1539,1569,1621,1702,1704,1748,1778,1825,1862,1891,1908,1986,2015,2060,2075,2187,2191,2213,2228,2239,2255,2278,2300,2309,2338,2352,2378,2401,2423,2436,2455,2462,2475,2541,2578,2622,2633,2671,2686,2713,2726,2753,2786,2810,2843,2930,2954,2993,3030,3324,3428,3445,3493,3632,3669,3706,3955,3994,4099,4128,4172,4191,4231,4262,4300,4327,4362,4511,4611,4662,4668,4672,4694,4747,4755,4762,4814,4830,4864,4909,4961,4974,4988,5132,5208,5303,5350,5389,5412,5693,5743,5809,5829,5938,5945,5951,5958,	
EFG 4 477 4 26,32,39,45,	
2 16 477 16 22,46,55,65,231,991,3154,3389,3414,4417,4429,4860,5043,5187,5898,5940,	
cinfa 12 477 12 21,28,34,41,54,73,91,111,5939,5946,5952,5959,	
	olanzapina 1 477 1 20,	
MEDICAMENTO 2 477 2 19,4086,	
DEL 2 477 2 18,6050,	
NOMBRE 1 477 1 17,	
1 19 477 19 16,135,151,1106,2706,3319,3359,3395,3600,3942,4088,4160,4456,5256,5408,5549,5773,5774,5883,	
ocasiones 6 477 6 716,1610,1735,3411,3575,3635,	
información 2 477 2 13,3466,	
investigador 1 477 1 1008,	
Toda 1 477 1 11,	
cardiovascular 1 477 1 4060,	
medicamento 7 477 7 10,15,976,1873,2124,2151,5984,	
Basica 1 477 1 8,	
	Información 1 477 1 7,	
28 4 477 4 5,5943,5949,5962,	
comprimidos 11 477 11 4,6,25,31,38,44,5929,5944,5950,5957,5965,	
mg 25 477 25 3,24,30,37,43,57,60,75,78,94,98,113,116,250,261,271,402,572,3929,3944,4609,5942,5948,5955,5961,	
5 33 477 33 2,23,29,36,56,59,74,77,93,97,228,281,399,571,679,681,992,1103,1107,1559,2153,3328,4081,4334,4859,4883,5039,5076,5424,5922,5941,5947,5954,	
CINFA 1 477 1 1,	
OLANZAPINA 1 477 1 0,	
